Arctoris, Molecule join forces on drug discovery
The news comes as drug discovery rates are declining, the price of bringing a drug to market is increasing, and return on investment (ROI) on R&D is expected to hit 0% in the next few years.
Read More
Tag: Arctoris
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
